|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Drs Lin and Peto had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Albain — Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: Abraxis BioScience, Genentech BioOncology, Genomic Health Inc. Dr Hudis — Consulting Fees: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Contracted Research: Kosan Biosciences; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP; Ownership Interest: Genomic Health Inc. Dr Jones — Consulting Fees: Pfizer Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis. Dr Miller — Consulting Fees: Genentech BioOncology; Contracted Research: Genentech BioOncology, Sanofi-Aventis. Dr O’Shaughnessy — Consulting Fees: Biogen Idec, Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, Pfizer Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Abraxis BioScience, Eli Lilly and Company, Sanofi-Aventis.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
 |
 |
EDITOR'S NOTE
San Antonio adventure, 2007
Neil Love, MD
- Select publications
INTERVIEWS
Stephen E Jones, MD
- Select publications
Sir Richard Peto, FRS
- Select publications
Kathy S Albain, MD
- Select publications
Roundtable Discussion
- Select publications
Joyce O’Shaughnessy, MD
- Select publications
Nancy U Lin, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
